This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity.
GLP-1 receptor agonists (RA), such as Ozempic and Mounjaro, were initially designed to help manage blood sugar in type 2 diabetes. Now, they are reshaping the landscape of obesity treatment and metabolic health with impacts that go far beyond the scale.
“About 1 in 8 adult Americans has already used GLP-1 drugs. That is 41 million Americans,” said Kim Fisher, director of programs at The UC Davis Innovation Institute for Food and Health (IIFH). “Lowering prices might encourage more people who might benefit from these medications to start using them.”
…
